Authors: Qi CZ, Lin Y, Li Y, Vu T, Gelinas D, Lizarraga AA, Blein C, De Ruyck F, Shi L.
Editor's Choice
Journal of the Neurological Sciences | Impact of corticosteroid use on comorbidities in patients with myasthenia gravis in the US National Veterans Affairs Health Network, 2026
Article Link: https://doi.org/10.1016/j.jns.2025.125716
A large longitudinal cohort study examines the long-term risks associated with corticosteroid use in patients with myasthenia gravis (MG), drawing on over two decades of data from the U.S. Veterans Affairs Health Care Network. The study compares patients with MG to matched non-MG controls to assess how corticosteroid exposure influences the development of common comorbidities over time.
The findings show that corticosteroid use is associated with a significantly higher risk of new-onset comorbidities in both MG and non-MG populations, with particularly notable increases among patients with MG receiving medium- to high-dose therapy. Elevated risks were observed for diabetes, infections, osteoporosis, cardiovascular disease, as well as glaucoma and depression at specific dose levels.
Read the full article for a detailed analysis of dose-related risks and why these results support strategies aimed at reducing long-term corticosteroid exposure in myasthenia gravis management.
Web design by Tribal Systems